{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:01:11Z","timestamp":1768881671598,"version":"3.49.0"},"reference-count":28,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN) carries a poor prognosis; however, immune checkpoint inhibitors have emerged as critical therapeutic options. Although the KEYNOTE-048 trial established the efficacy of pembrolizumab, the population was restricted to major sites (e.g., oral cavity, oropharynx, hypopharynx, and larynx), excluding subsites such as the paranasal sinuses and nasopharynx. To evaluate outcomes in these populations, we conducted a multicenter retrospective study of 167 patients with R\/M SCCHN treated with pembrolizumab between December 2019 and February 2022. The cohort comprised 127 patients with tumors in included sites and 27 in excluded subsites. Primary endpoints included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and immune-related adverse events (irAEs). In the excluded subsite group, median OS was 15.2 months (1-year rate: 70.6%), and median PFS was 4.9 months (1-year rate: 21.2%). The ORR was 22.2% and the DCR was 59.3%. The incidence of irAEs was 25.9%, with Grade \u2265 3 events in 3.7%. Survival outcomes did not differ significantly from those in included sites. These findings suggest the potential efficacy and safety of pembrolizumab in subsites excluded from KEYNOTE-048, warranting validation in prospective trials.<\/jats:p>","DOI":"10.3390\/curroncol33010057","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:58:54Z","timestamp":1768834734000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial"],"prefix":"10.3390","volume":"33","author":[{"given":"Gai","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-1137","authenticated-orcid":false,"given":"Isaku","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo 193-0998, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kishida","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Aihara","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Hanyu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-1001","authenticated-orcid":false,"given":"Yuri","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Tokashiki","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo 193-0998, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-9384","authenticated-orcid":false,"given":"Kaho","family":"Momiyama","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-3512","authenticated-orcid":false,"given":"Takashi","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiomi","family":"Kushihashi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo 108-8329, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Masubuchi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo 108-8329, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo 108-8329, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo 160-0023, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0959-8049(00)00054-X","article-title":"Natural history of untreated head and neck cancer","volume":"36","author":"Kowalski","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"ref_2","first-page":"5499","article-title":"Survival After Distant Metastasis in Head and Neck Cancer","volume":"35","author":"Wiegand","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1288\/00005537-199410000-00003","article-title":"Distant metastases from head and neck squamous cell carcinomas","volume":"104","author":"Calhoun","year":"1994","journal-title":"Laryngoscope"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","article-title":"NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 2.2025","volume":"23","author":"Colevas","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2014.97","article-title":"Sinonasal carcinoma: Clinical, pathological, genetic and therapeutic advances","volume":"11","author":"Llorente","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12105-022-01420-1","article-title":"Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands","volume":"16","author":"Hyrcza","year":"2022","journal-title":"Head Neck Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kang, B.C., Yi, S.E., Kang, W.S., Ahn, J.H., Park, H.J., and Chung, J.W. (2025). Treatment outcomes and prognostic factors in external auditory canal squamous cell carcinoma. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0339860"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): An open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"171","author":"Even","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e71391","DOI":"10.1002\/cam4.71391","article-title":"Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and\/or Metastatic Sinonasal Squamous Cell Carcinoma","volume":"14","author":"Lein","year":"2025","journal-title":"Cancer Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_16","unstructured":"US Department of Health and Human Services (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fan, Z., Hui, R., Ju, H., Wu, Y., Ma, X., Song, H., Liu, Y., Rui, M., Geng, X., and Zhao, M. (2024). The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A single center, real world study in China. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1360657"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.21873\/anticanres.16438","article-title":"Effects of Pembrolizumab in Recurrent\/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study","volume":"43","author":"Okada","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Davis, A.M., Rapley, A., Dawson, C.W., Young, L.S., and Morris, M.A. (2021). The EBV-Encoded Oncoprotein, LMP1, Recruits and Transforms Fibroblasts via an ERK-MAPK-Dependent Mechanism. Pathogens, 10.","DOI":"10.3390\/pathogens10080982"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.oraloncology.2014.02.006","article-title":"Etiological factors of nasopharyngeal carcinoma","volume":"50","author":"Tsao","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12105-017-0795-0","article-title":"Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland","volume":"11","author":"Seethala","year":"2017","journal-title":"Head Neck Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Loperfido, A., Cavaliere, C., Fionda, B., Masieri, S., Bellocchi, G., Re, M., and Tomasetti, M. (2025). The Emerging Role of MicroRNAs in Nasal Inflammatory Diseases and Tumors: From Bench to Bedside. Genes, 16.","DOI":"10.3390\/genes16030295"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.21873\/anticanres.15948","article-title":"Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan","volume":"42","author":"Sano","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13046-022-02457-4","article-title":"Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment","volume":"41","author":"Jiang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41590-022-01312-0","article-title":"Single-cell profiling identifies mechanisms of inflammatory heterogeneity in chronic rhinosinusitis","volume":"23","author":"Wang","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:22:08Z","timestamp":1768836128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010057"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010057","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}